DK1294390T3 - Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet - Google Patents

Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet

Info

Publication number: DK1294390T3
Authority: DK; Denmark
Prior art keywords: cop; nervous system; polypeptide; polypeptides; copolymer
Prior art date: 2000-06-07

Application number

DK01906632T

Other languages

English (en)

Inventor

Michal Eisenbach-Schwartz

Eti Yoles

Jonathan Kipnis

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-07

Filing date

2001-01-22

Publication date

2006-04-03

2001-01-22 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2006-04-03 Application granted granted Critical

2006-04-03 Publication of DK1294390T3 publication Critical patent/DK1294390T3/da

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
229920001184 polypeptide Polymers 0.000 title abstract 5
210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 title 1
229920001577 copolymer Polymers 0.000 title 1
229930195712 glutamate Natural products 0.000 title 1
230000004112 neuroprotection Effects 0.000 title 1
230000001988 toxicity Effects 0.000 title 1
231100000419 toxicity Toxicity 0.000 title 1
210000003169 central nervous system Anatomy 0.000 abstract 2
210000005036 nerve Anatomy 0.000 abstract 2
210000000653 nervous system Anatomy 0.000 abstract 2
230000004770 neurodegeneration Effects 0.000 abstract 2
210000001428 peripheral nervous system Anatomy 0.000 abstract 2
230000008929 regeneration Effects 0.000 abstract 2
238000011069 regeneration method Methods 0.000 abstract 2
208000027418 Wounds and injury Diseases 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
230000006378 damage Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Hematology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Mycology (AREA)
Microbiology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Addiction (AREA)
Psychology (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK01906632T 2000-06-07 2001-01-22 Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet DK1294390T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US20979900P	2000-06-07	2000-06-07
US62021600A	2000-07-20	2000-07-20

Publications (1)

Publication Number	Publication Date
DK1294390T3 true DK1294390T3 (da)	2006-04-03

Family

ID=26904524

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01906632T DK1294390T3 (da)	2000-06-07	2001-01-22	Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet

Country Status (16)

Country	Link
US (1)	US20020037848A1 (da)
EP (1)	EP1294390B1 (da)
JP (1)	JP4328090B2 (da)
KR (1)	KR20030007397A (da)
CN (1)	CN100438906C (da)
AT (1)	ATE314860T1 (da)
AU (1)	AU783031B2 (da)
CA (1)	CA2398277C (da)
CY (1)	CY1105263T1 (da)
DE (1)	DE60116467T2 (da)
DK (1)	DK1294390T3 (da)
ES (1)	ES2256200T3 (da)
IL (2)	IL150801A0 (da)
MX (1)	MXPA02007109A (da)
NZ (1)	NZ520282A (da)
WO (1)	WO2001093893A2 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL141021A0 (en)	1998-07-23	2002-02-10	Yeda Res & Dev	Treatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en)	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en)	2000-02-18	2006-04-04	Yeda Research And Development Co., Ltd.	Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0302333A3 (en) *	2000-06-05	2005-07-28	Teva Pharma	The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
WO2002076503A1 (en)	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7429374B2 (en)	2001-12-04	2008-09-30	Teva Pharmaceutical Industries, Ltd.	Process for the measurement of the potency of glatiramer acetate
US7351686B2 (en) *	2001-12-06	2008-04-01	Yeda Research And Development Co. Ltd.	Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
ES2386435T3 (es)	2003-01-07	2012-08-21	Yeda Research And Development Co., Ltd.	Vacuna en forma de gotas oculares que contiene copolímero 1 para inmunización terapéutica
WO2005030955A1 (ja) *	2003-09-29	2005-04-07	Chugai Seiyaku Kabushiki Kaisha	Nk細胞に発現するタンパク質
JP2007507541A (ja) *	2003-10-03	2007-03-29	ベイヒルセラピューティクスインコーポレーティッド	修飾型の規則正しいペプチドによる脱髄性自己免疫性疾患の治療方法
JP5456235B2 (ja)	2003-11-12	2014-03-26	イエダリサーチアンドデベロップメントカンパニーリミテッド	神経変性疾患を治療するためのワクチン及び方法
JP4808631B2 (ja) *	2003-12-09	2011-11-02	イエダリサーチアンドデベロップメントカンパニーリミテッド	精神医学的障害の治療用のコポリマー１を含む方法及びワクチン
JP5495490B2 (ja)	2004-05-07	2014-05-21	アレストレーディングエスエイ	ランダム共重合体を用いる疾患の治療方法
ZA200702591B (en)	2004-09-09	2009-03-25	Teva Pharma	Process for preparation of mixtures of polypeptides using purified hydrobromic acid
ES2541780T3 (es) *	2004-11-29	2015-07-24	Yeda Research And Development Co., Ltd.	Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
US8378072B2 (en)	2006-04-13	2013-02-19	Declion Pharmaceuticals, Inc.	Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability
WO2009040814A1 (en)	2007-09-24	2009-04-02	Hadasit Medical Research Services & Development Ltd	Use of copolymer 1 for treatment of muscular dystrophy
AP3467A (en)	2007-10-16	2015-11-30	Peptimmune Inc	Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
WO2009063459A2 (en) *	2007-11-13	2009-05-22	Yeda Research And Development Co. Ltd	Synthetic peptide copolymers for treatment of neurodevelopmental disorders
NZ598661A (en)	2009-08-20	2013-02-22	Yeda Res & Dev	Low frequency glatiramer acetate therapy
HUE060304T2 (hu) *	2010-01-04	2023-02-28	Mapi Pharma Ltd	Glatiramer acetátot tartalmazó depó rendszer
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8377885B2 (en)	2010-01-04	2013-02-19	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) *	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CA2814500A1 (en)	2010-10-11	2012-04-19	Teva Pharmaceutical Industries Ltd	Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
WO2012143924A1 (en)	2011-04-21	2012-10-26	Mapi Pharma Ltd.	Random pentapolymer for treatment of autoimmune diseases
HK1200274A1 (en)	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2014037952A1 (en)	2012-09-10	2014-03-13	Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science	Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh)	2016-08-31	2019-07-05	Mapi医药公司	包含醋酸格拉替雷的储库系统
CN110382052A (zh)	2017-03-26	2019-10-25	Mapi医药公司	用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2022246250A1 (en) *	2021-05-20	2022-11-24	Washington University	Neuroprotective compositions and methods
KR20230128606A (ko) *	2022-02-28	2023-09-05	경상국립대학교산학협력단	티로신을 유효성분으로 함유하는 알츠하이머병의 예방, 개선 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL36670A (en) *	1971-04-21	1974-09-10	Sela M	Therapeutic basic copolymers of amino acids
IL113812A (en) *	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use
EP1054880A1 (en) *	1998-02-13	2000-11-29	Autoimmune, Inc.	TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES

2001
- 2001-01-22 EP EP01906632A patent/EP1294390B1/en not_active Expired - Lifetime
- 2001-01-22 MX MXPA02007109A patent/MXPA02007109A/es active IP Right Grant
- 2001-01-22 US US09/765,301 patent/US20020037848A1/en not_active Abandoned
- 2001-01-22 AT AT01906632T patent/ATE314860T1/de active
- 2001-01-22 DE DE60116467T patent/DE60116467T2/de not_active Expired - Lifetime
- 2001-01-22 AU AU34518/01A patent/AU783031B2/en not_active Expired
- 2001-01-22 IL IL15080101A patent/IL150801A0/xx active IP Right Grant
- 2001-01-22 WO PCT/US2001/002118 patent/WO2001093893A2/en not_active Ceased
- 2001-01-22 NZ NZ520282A patent/NZ520282A/en not_active IP Right Cessation
- 2001-01-22 KR KR1020027009275A patent/KR20030007397A/ko not_active Ceased
- 2001-01-22 CA CA2398277A patent/CA2398277C/en not_active Expired - Lifetime
- 2001-01-22 ES ES01906632T patent/ES2256200T3/es not_active Expired - Lifetime
- 2001-01-22 CN CNB018065910A patent/CN100438906C/zh not_active Expired - Lifetime
- 2001-01-22 JP JP2002501464A patent/JP4328090B2/ja not_active Expired - Fee Related
- 2001-01-22 DK DK01906632T patent/DK1294390T3/da active
2002
- 2002-07-18 IL IL150801A patent/IL150801A/en unknown
2006
- 2006-02-16 CY CY20061100219T patent/CY1105263T1/el unknown

Also Published As

Publication number	Publication date
WO2001093893A3 (en)	2002-04-04
ES2256200T3 (es)	2006-07-16
CY1105263T1 (el)	2010-03-03
MXPA02007109A (es)	2002-12-13
EP1294390A2 (en)	2003-03-26
US20020037848A1 (en)	2002-03-28
WO2001093893A2 (en)	2001-12-13
IL150801A (en)	2007-10-31
HK1058892A1 (zh)	2004-06-11
CN1462190A (zh)	2003-12-17
AU3451801A (en)	2001-12-17
DE60116467T2 (de)	2006-11-02
KR20030007397A (ko)	2003-01-23
JP2004507460A (ja)	2004-03-11
IL150801A0 (en)	2003-02-12
DE60116467D1 (de)	2006-03-30
NZ520282A (en)	2004-09-24
JP4328090B2 (ja)	2009-09-09
EP1294390B1 (en)	2006-01-04
CA2398277C (en)	2013-09-03
AU783031B2 (en)	2005-09-15
CA2398277A1 (en)	2001-12-13
CN100438906C (zh)	2008-12-03
ATE314860T1 (de)	2006-02-15

Publication	Publication Date	Title
DK1294390T3 (da)	2006-04-03	Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
DK1248643T3 (da)	2005-11-07	Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi
WO1999060021A3 (en)	2000-06-15	Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
IL267381A (en)	2019-08-29	A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
TR199802421T2 (xx)	1999-02-22	Doku yenilenmesini d�zenleyen maddeler.
NZ504026A (en)	2002-12-20	Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE186219T1 (de)	1999-11-15	Kombination von antihormonale und bindende moleküle zur krebsbehandlung
HUP9904023A2 (hu)	2000-03-28	Leptin antagonisták alkalmazása inzulin rezisztencia kezelésére II. típusú cukorbajban
HRP20010877B1 (hr)	2011-02-28	Pripravci za prevenciju i liječenje amiloidogenskih bolesti
ATE255128T1 (de)	2003-12-15	Peptid-immitierende substanzen in der krebstherapie
DE69835279D1 (de)	2006-08-31	Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
DK0914144T3 (da)	2001-04-09	Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi
DE60032486D1 (de)	2007-02-01	Prion protein peptide und deren verwendung
AR045870A1 (es)	2005-11-16	Terapia de combinacion para la infeccion de virus de hepatitis c
DE69719754D1 (de)	2003-04-17	Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
EP1351968A4 (en)	2004-04-28	MUTATIONS IN THE ALPHA1 SUBUNIT OF THE NEURONAL GENE SODIUM CHANNEL, ASSOCIATED POLYPEPTIDES, AND TREATMENT OF GEFS + SYNDROME (GENERALIZED EPILEPSY WITH FEBRILIS + CRISIS)
ATE466870T1 (de)	2010-05-15	Peptide und deren verwendung in der behandlung von krankheiten des zentralen nervensystems
DE68906066D1 (de)	1993-05-27	Peptid und dessen salze und antiallergische peptidmittel, welche diese peptide enthalten.
WO1996020950A3 (en)	1996-09-12	Compositions and methods for treating rheumatoid arthritis
ATE247965T1 (de)	2003-09-15	Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung
DE60121449D1 (de)	2006-08-24	Behandlung von hepatitis c mit thymosin und pegyliertem interferon
EA200000514A1 (ru)	2001-06-25	Способ лечения эректильной дисфункции